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Abstract
Background: Evidence-based guidelines have the potential to improve healthcare. However, their de-novo-
development requires substantial resources – especially for complex conditions, and adaptation may be biased by
contextually influenced recommendations in source guidelines. In this paper we describe a new approach to
guideline development – the systematic guideline review method (SGR), and its application in the development of
an evidence-based guideline for family physicians on chronic heart failure (CHF).
Methods: A systematic search for guidelines was carried out. Evidence-based guidelines on CHF management in
adults in ambulatory care published in English or German between the years 2000 and 2004 were included.
Guidelines on acute or right heart failure were excluded. Eligibility was assessed by two reviewers, methodological
quality of selected guidelines was appraised using the AGREE instrument, and a framework of relevant clinical
questions for diagnostics and treatment was derived. Data were extracted into evidence tables, systematically
compared by means of a consistency analysis and synthesized in a preliminary draft. Most relevant primary sources
were re-assessed to verify the cited evidence. Evidence and recommendations were summarized in a draft
guideline.
Results: Of 16 included guidelines five were of good quality. A total of 35 recommendations were systematically
compared: 25/35 were consistent, 9/35 inconsistent, and 1/35 un-rateable (derived from a single guideline). Of
the 25 consistencies, 14 were based on consensus, seven on evidence and four differed in grading. Major
inconsistencies were found in 3/9 of the inconsistent recommendations. We re-evaluated the evidence for 17
recommendations (evidence-based, differing evidence levels and minor inconsistencies) – the majority was
congruent. Incongruity was found where the stated evidence could not be verified in the cited primary sources,
or where the evaluation in the source guidelines focused on treatment benefits and underestimated the risks. The
draft guideline was completed in 8.5 man-months. The main limitation to this study was the lack of a second
reviewer.
Conclusion: The systematic guideline review including framework development, consistency analysis and
validation is an effective, valid, and resource saving-approach to the development of evidence-based guidelines.
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Evidence-based clinical practice guidelines have consider-
able potential to improve health care, and their interna-
tional production has increased substantially over the past
two decades [1-3]. However, the de-novo development of
an evidence-based guideline requires considerable time,
expertise and resources [4,5], the latter of which are lim-
ited, even in developed countries [6,7]. It was therefore
suggested that their development should be based on the
adaptation of existing guidelines [8].
A number of projects have sought to adapt or adopt exist-
ing guidelines [9-14], on topics ranging from HIV/AIDS
[10] to the management of acute low back pain [14].
Each, in its own way, has highlighted the challenges of
deriving new guidelines from existing material. Deficient
development methods [15-20], subjectivity [21] and con-
flicts of interest [22,23] in the source guidelines may all
lead to biases.
Additionally, implicit normativity has been shown to be
inherent in guidelines – from the search for and critical
appraisal of evidence, to its presentation, and the formu-
lation of recommendations [24]. Contextual features arise
from subject and financial constraints [25,26], ethical
considerations and social influences [27-29], as well as
practical necessities [30]. But presuppositions and values
change, vary between cultures and healthcare systems,
and are sometimes inconsistent, even within healthcare
systems [30-34]. They may distort an adapted guideline to
suit a different target context. Moreover, explaining and
addressing context-specific normative considerations
have been seen as a necessary condition for the successful
implementation of guidelines [27].
All of these issues give rise to methodological challenges
for adaptation processes. In recognition of this, the
ADAPTE group [35] has proposed a seven-step framework
which they call 'trans-contextual' adaptation. Fervers et al.
[35] pointed out that it is of crucial importance to analyze
the coherence between evidence and recommendations
and to take culture and systems into account, but they did
not provide the practical means to deal with this problem.
In this paper we describe a new method that we have
named the systematic guideline review (SGR). The SGR
method was designed to take both methodological short-
comings and context-specific normative issues in source
guidelines into consideration, in order to develop a valid
guideline for a different target context in a resource saving
manner.
The SGR was conducted as the first step in the develop-
ment of a new guideline on chronic heart failure for use
by family physicians in Germany. After having carried out
the SGR, the resulting draft guideline underwent further
development in accordance with institutional standards
[36], which are out of scope of this paper: To ensure the
involvement of stakeholders and target users, this com-
prised a multistage internal and external peer review, a
multi-professional, interdisciplinary formal consensus
that included a patients' representative (nominal group
process), and a pilot testing phase. The final guideline was
authorized by the German Society of General Practice and
Family Medicine (DEGAM) and published in 2006 [37].
In our article we focus on the systematic guideline review.
Methods
To develop an evidence-based guideline on chronic heart
failure (CHF) for use in German primary care we defined,
a priori, the key premises of the target guideline: the defi-
nition of the target condition, its epidemiology, the target
setting, the need for change in healthcare, and the out-
come parameters of interest.
We designed the SGR method comprising the nine steps
grey tagged in FIGURE 1.
Systematic guideline search
In March 2004 one of us (CM) performed a systematic lit-
erature search for existing guidelines in MEDLINE, The
Cochrane Library, DARE, and HSTAT; combining control-
led terms and free text, complemented by a comprehen-
sive hand search of web-based resources (see Additional
file 1, Tables W1 and W2) and in reference lists of the
retrieved guidelines.
Guideline Selection
Based on predefined criteria, two reviewers (CM, JG) inde-
pendently appraised the retrieved guideline-documents
for eligibility (yes or no). Discrepancies were resolved by
consensus, and kappa-statistics were calculated for
observer variability according to Cohen [38]. To be
included a guideline had to be (1) dedicated to adult
patients with chronic heart failure (CHF), (2) evidence-
based, i.e. evidence levels (and/or a grading) were
reported in the majority of recommendations with a clear
link to supporting evidence, (3) released in the year 2000
or later, and (4) published in English or German.
A guideline was excluded, if it referred exclusively to pedi-
atric patients, isolated right heart failure, special or inpa-
tient care, or no information on development methods
was given (at least, an institutional standard of the devel-
oping organization had to be provided). Guidelines with
a focus only on particular aspects of heart failure manage-
ment (e.g. guidelines on echocardiography) were
excluded from the SGR.
Quality appraisal of guidelines
The quality of the guideline was assessed using the stand-
ardized Appraisal of Guidelines Research and Evaluation
(AGREE) instrument [39,40]. AGREE consists of 23 itemsPage 2 of 15
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means of four-point Likert scales. The items are organized
into six independent domains. Domain scores are calcu-
lated by summing up the scores of the items per domain
and are standardised as a percentage of the maximum pos-
sible score for that domain. [39]. There is no universal
agreement on specific cut off scores to identify high qual-
ity guidelines, and differing approaches are applied
[41,42]. To rate the overall guideline quality we defined a
median target and result score per guideline (calculated as
the median of the standardized domain scores over all
domains) of 0.5 or above as indicating good quality.
AGREE is suggested for multiple raters. The appraisal is
based on the consideration of the whole guideline and is
therefore of wider scope than the evidence review and syn-
thesis reported here. Nevertheless, it does include any rec-
ommendations on diagnosis, monitoring, or prevention
and the proposed multiple rater scheme is thus rather
time-consuming. Because we had only limited resources
available to us, we performed a single rating (CM) for this
step of the guideline development process.
Framework and data extraction
To build a framework of relevant issues, clinical questions
from the included guidelines were derived by one
reviewer (CM), appraised for their relevance and priori-
tized in terms of the target context by three others (JG,
MB, FMG). For each clinical question the data were extrac-
tedinto evidence tables of a standardized format which
included recommendation(s), evidence level(s), grading,
critical appraisal of evidence, and cited sources.
Consistency analysis
One reviewer (CM) systematically compared guideline
recommendations for every clinical question for their
external consistency (e.g. between guidelines), and their
reported evidence. We categorized our findings into six
types (Table 1): four types of consistency and two types of
inconsistency (major and minor). The categories were
built on both dimensions (external consistency and evi-
dence base) to support a further action plan for guideline
development: low levels of evidence as well as inconsist-
encies between guidelines indicated the need for further
research. The classification system was drafted by two of
us (CM and MB) and consented with the others (JG, AH,
FMG). One reviewer (CM) synthesized the information
(recommendations, their consistency, as well as the
reported underlying evidence from the included guide-
lines) in a preliminary draft.
Validation
For a critical re-appraisal of whether recommendations
were supported by valid study results, the most relevant
evidence cited in the included guidelines was selected by
Development of the Evidence-based Guideline on Chronic H art Failure in Primary CarFigure 1
Development of the Evidence-based Guideline on 
Chronic Heart Failure in Primary Care. Gray Tagged: 
The Systematic Guideline Review.Page 3 of 15
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Centre for Evidence-Based Medicine [43]. Predominantly
systematic reviews with or without meta-analyses were re-
evaluated, along with clinical studies of an appropriate
design when secondary publications did not provide the
desired evidence. The selected studies were re-evaluated
for their internal and external validity. For the assessment,
checklists from the German Working Group on Health
Technology Assessment (see Additional file 1, non-scor-
ing standardized instruments, Table W3) were used, since
one of us (CM) was trained and experienced in its use
[44]. In particular, the studies were investigated for inher-
ent bias, which might have influenced results, and for the
applicability of their results (in accordance with the
defined key premises of the target guideline: study popu-
lation representative of target population, clinically rele-
vant outcomes reported in the study, setting of the study
appropriate with regard to the target setting).
Draft guideline
Finally, the evidence and recommendations were synthe-
sized in a draft of the target guideline, and the results and
possible methodological flaws of the included source-
guidelines, and the re-assessed studies, were discussed.
For specified clinical questions without identified high-
quality evidence and for the necessary update-searches to
ensure the actuality of the guideline, a structured list was
formed to define the need for further research.
Results
Literature Search and Selection
Our literature search resulted in 699 citations, of which 52
were potentially relevant. A total of 16 evidence-based
guidelines met our inclusion criteria ( FIGURE 2). The
inter-observer variability was excellent (one discrepancy;
κ = 0.95). Of the included guidelines (Table 2), five were
from Germany [45-49], four from the U.S. [50-54], two
each from Canada [55-57] Australia & New Zealand
[58,59], and one each from Finland [60], the U.K. [61],
and Europe [62]. The context and setting of the guidelines
varied: five guidelines were prepared for a specific health-
care setting (e.g. ambulatory care in a health maintenance
organization) [48,51-54,57], one guideline was directed
towards CHF management throughout Europe [62], one
guideline did not specify any target group [49], and the
remaining guidelines referred to national healthcare. The
scope of the guidelines varied considerably (all addressed
pharmacotherapy in heart failure, 13/16 non-pharmaco-
Table 1: Categories of Consistency and Inconsistency
Type Definition Further Action Plan for Guideline Development
Consistency
(1) Recommendations are consistent in content, evidence level 
and grading, and based on a large body of high level evidence 
(e.g. multiple primary or secondary studies of high internal and 
external validity)
Verification of cited sources with highest evidence level, and update 
searches, if necessary
(2) Recommendations are consistent in content, evidence level 
and grading, and based on a small body of high level evidence 
(e.g. a single or a few primary studies of high internal and external 
validity)
Verification of cited sources, further research on safety aspects in 
particular, and update searches
(3) Recommendations are consistent in content, evidence level 
and grading, and based on evidence from studies of low level 
evidence (e.g. studies with design-related biases or where 
methodological flaws reduce internal or external validity) or based 
on expert opinion (where evidence is lacking)
Further research on evidence
(4) Recommendations are consistent in content, but evidence 
levels and grading conflict
Verification of cited sources, and update searches
Inconsistency
(A) Recommendations are completely inconsistent,
neither a mainstream trend nor even a common denominator can 
be identified
Further research on evidence
(B) Recommendations are consistent in the majority of 
guidelines, but differing or even conflicting recommendations 
are to be found in a minority
Verification of cited sources to decide whether further research is 
necessary, and update-searchesPage 4 of 15
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Table 2: Characteristics of Included Guidelines
Source Organisation, Country 
of Origin
Covered Scope† No. of Authors Literature Search: 
Period/Databases
No. of References
ACC/AHA 2001 [50] American College of 
Cardiology/American Heart 
Association, U.S.A.
D, T 14 Period not specified 
MEDLINE, EMBASE
573
AKDAE 2001 [45] Drug Commission of the 
German Medical Association, 
Germany
P Not specified No systematic search 216
CCS 2001 [56], 2002/3 
[55]
Canadian Cardiovascular 
Society, Canada
D, T Not specified Period not specified 
MEDLINE
2001: 79; 2002/3: 42
DGK 2001 [46] German Cardiac Society, 
Germany
T 2 1990–2000; Databases: not 
specified
213
DieM 2003/2004 [47] Institute for Evidence-Based 
Medicine, Germany
T 3 Period not specified (Last 03/
2003); MEDLINE, Cochrane 
Library, „Best Evidence"
42
Duodecim 2004 [60] The Finnish Medical Society 
Duodecim, Finland
D, T Not specified Period not specified (Last 03/
2004); DARE, „Best 
Evidence"
Ca. 50††
DVA & VHA 2002 [51] Department of Veterans 
Affairs & Veterans Health 
Administration, U.S.A.
P 14* Update search 01/2001 to 11/
2002; MEDLINE
197
ESC 2002/2001 [62] European Society of 
Cardiology, (Europe)
D, T 18 Not specified 196
ICSI 2003 [52] Institute for Clinical System 
Improvement, U.S.A.
D, T 11 Not specified Ca. 50
LLGH 2003 [48] 'Leitliniengruppe' (Group of 
Family Physicians in Hesse), 
Germany
(D), T 2 Period not specified 
MEDLINE
72
NHF/Austr & SANZ 
2002 [58]
National Heart Foundation of 
Australia and Cardiac Society 
of Australia & New Zealand
D, T 33 Not specified 143
NHF/NZ 2001 [59] The National Heart 
Foundation of New Zealand
D, T 19 Period not specified (Last 04/
2000); MEDLINE
44
NICE 2003 [61] The National Collaborating 
Centre for Chronic 
Conditions/National Institute 
for Clinical Excellence, United 
Kingdom
D, T 15** Start of the Database until 
09/2002; MEDLINE, EMBASE, 
CINAHL, PsycINFO, AMED, 
Cochrane Library, EconLit
347‡
OPOT 2000 [57] Ontario Program for Optimal 
Therapeutics, Canada
P Not specified Not specified 24
UM 2001 [53,54] University of Michigan, U.S.A. D, T 6 1994 – 02/1998, + hand 
searches until 2001; 
MEDLINE
50
UWH 2001 [49] Faculty of Medicine, 
University Witten/Herdecke, 
Germany
D, T 5 + 2‡‡ Not specified 157
†Limitation on recommendations with evidence levels and/or grading; ††Ascertainment possibly incomplete because of document structure (internet-based 
version with links to other documents); *Supported by 13 members of The Medical Advisory; **Support from 14 members of the Guideline Reference 
Group; ‡Additional citations in evidence tables not counted; ‡‡Additional advisors from specialized care; Abbreviations: D – diagnostics, (D) – diagnostics 
partly, T – therapy, P – pharmacotherapy only
BMC Health Services Research 2009, 9:74 http://www.biomedcentral.com/1472-6963/9/74logical therapy, 10/16 diagnostics), as did the size of the
guideline development groups (2 to 33; median 13), the
number of citations (24 to 573; median 132), the volume
of the full text version (16 to 163 pages in the long ver-
sions), and the quantity and layout of additional tools. A
complete list of excluded guidelines, together with the rea-
sons for exclusion, is provided as additional web-material
(see Additional file 1, Table W4).
Appraisal of the Methodological Quality
Five guidelines [48,50-52,61] were found to be of high
quality according to our criteria. Methodological quality
varied broadly between both guidelines (ranging from 0.2
to 0.7) and domains (Table 3) and the key results of the
most important domains for the SGR were as follows: In
domain 3 "rigour of development" 7/16 guidelines scored
well: 13/16 used systematic methods in their search for
evidence; 12/16 explained methods for formulating their
recommendations – two of which included formal con-
sensus techniques; 12/16 provided information on the
update process – seven in detail. All guidelines discussed
health benefits, side effects, and the risks of applying most
(or at least the key) recommendations, 11/16 reported on
a formal external peer review process. The main weakness
appeared in the description of how the evidence was
selected: only 4/16 guidelines reported explicit criteria. In
domain 6 "editorial independence" four guidelines
scored 0.0 (no information about funding source, no
financial disclosures for their group members), one guide-
line scored 1.0 (full information on financing, and decla-
rations on potential conflicts of interest), the remainder in
between.
Framework Development and Data Extraction
In a stepwise approach we derived 27 clinical questions
for the framework of our target-guideline. Some questions
were partly complex, i.e. they comprised more than one
research question (e.g. 'Should patients be encouraged to
do exercise training, and if so, what intensity and duration
should be aimed for?'). To extract the data we entered all
relevant information into evidence tables in the above
mentioned format.
Consistency Analysis
Within the framework we identified 35 recommenda-
tions. Of these, 25 recommendations were consistent,
nine were inconsistent, and one was not rateable (derived
from a single guideline). Of 25 consistencies, seven were
based on strong evidence (types 1 and 2), 14/25 on weak
evidence or expert consensus (type 3), and 4/25 were con-
sistent in content, but had different evidence levels (type
4). Only one inconsistent recommendation (a minor
inconsistency about salt and fluid restriction) was based
on expert consensus, the remaining inconsistencies dif-
fered in their evaluation of the empirical findings (types A
and B).
While we found type 1-, 2-, and 4-consistencies mainly in
recommendations on pharmacotherapy (Table 4), type 3-
consistencies addressed all kinds of clinical questions,
from diagnostics to education, monitoring, and the defi-
nition of interfaces to specialized ambulatory and in-
patient care.
Among nine inconsistencies we classified three as major
inconsistencies (type A): (1) The use of brain natriuretic
peptide testing in patients when CHF is suspected (Table
5); (2) Angiotensin II receptor blockers (ARB) in addition
to ACE inhibitors and beta-blockers (triple-therapy); and
(3) ARB in combination with ACE inhibitors in beta-
blocker-intolerant patients (substitution of beta-block-
ers).
Validation
Seventeen partly complex recommendations were catego-
rized as consistency types 1, 2, 4 (n = 11), and inconsist-
ency type B (n = 6) (Table 4). They were further examined
in the validation procedure, while type-3-consistencies
and major inconsistencies indicated the need for further
search for new evidence rather than validation (see Addi-
tional file 1, for a complete list of type-3-consistencies and
type-A-inconsistencies see Table W5).
To address the clinical questions under investigation the
guidelines cited 309 documents, of which we considered
21 studies for re-assessment: 14 systematic reviews (SR)
with or without meta-analyses, six RCTs and one post-hoc
subgroup analysis of an RCT, since this study was linked
to a warning sign in one guideline. The reasons for preclu-
sion of the remaining studies are given below (Table 6).
The validation procedure (Table 4) showed most of the
recommendations to be justified by the cited evidence
sources. Nevertheless, we found incongruity – three con-
cise examples are given below:
(1) Incongruity due to a lack of evidence
All included guidelines recommended the use of ACE
inhibitors in all NYHA classes including asymptomatic
patients. While 11 guidelines designed differentiated clin-
ical outcomes as therapeutic goals in asymptomatic
patients (e.g. improvement in prognosis and hospitaliza-
tion), three guidelines ranked evidence-level highest for a
mortality reduction in this subpopulation, and two guide-
lines used ambiguous formulations. We found no evi-
dence from the cited studies for a mortality reduction in
asymptomatic patients, since this subpopulation was
underrepresented in RCTs. Evidence was found only when
we identified an health technology assessment report inPage 6 of 15
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Results of the Systematic Guideline Search (Flowchart)Fig re 2
Results of the Systematic Guideline Search (Flowchart).
Search in electronic databases and on Websites of Clearinghouses: n=669 citations 
- MEDLINE: n=289 citations 
- National Guideline Clearinghouse: n=117 citations 
- Agency for Quality in Medicine (Germany): n=29 citations 
- Guideline International Network: n=11 citations 
- HSTAT and DARE: n=76 citations 
- The Cochrane Library: n=147 citations
Hand searches: 
n=30 citations  
N=699 citations  
n=647 irrelevant citations excluded after checking for title and abstract 
and removal of duplicates 
n=52 potentially relevant citations identified after liberal screening 
Not included in evaluation but used for background information:  
n=14 guidelines on specific aspects of heart failure management 
n=38 retrieved for in-/exclusion by two independent reviewers 
Formal exclusion n=22 guidelines: 
n=5 guidelines: no clear link between recommendation and supporting 
evidence  
n=9 guidelines: last update before 2000 
n=5 guidelines: publication language different from German or English 
n=1 guideline: for in-patient care only 
n=1 guideline: invalid version, timed out by an update 
n=1 guideline, as it was an adaptation of another already included 
guideline  
n=16 guidelines fulfilled formal inclusion and exclusion criteria 
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in recommendations for beta-blocker therapy in asympto-
matic patients without prior myocardial infarction.
(2) Incongruity due to the ambiguous use of evidence levels
Fourteen guidelines recommended the use of diuretics,
reported evidence levels and graded their recommenda-
tions: in 2/14 diuretics were recommended to reduce mor-
tality and morbidity in CHF. The supporting evidence was
ranked highest and linked to a systematic review includ-
ing meta-analysis (published in 2002) [75], which was
not accepted by another guideline on the basis of its
equivocal methodological quality. In 12 guidelines the
main therapeutic goal of diuretics was to control fluid
retention: 7/12 ranked the evidence highest, 2/12 second
highest and 2/12 lowest (expert opinion). We re-
appraised the meta-analysis of 17 small sample sized
RCTs and confirmed concerns about its methodological
quality (no discussion of the methodological quality of
included studies, homogeneity assumption after the χ2-
test detected no heterogeneity despite high clinical heter-
ogeneity between the studies, no sensitivity analyses to
test the robustness of the results). In conclusion, the evi-
dence level remained unclear: formally, multiple RCTs
have shown positive effects on (different) clinical out-
comes of diuretics, but the methodological quality of the
meta-analyses (and the RCTs themselves) give a high
probability of biased results.
(3) Other kinds of incongruence
The evaluation of pharmacotherapy in the source guide-
lines often focused on treatment benefits and underesti-
mated the risks, such as of adverse events, following the
combination of ARBs and ACE inhibitors, or the risk of
hyperkalemia following the use of aldosterone antago-
nists, as recently shown [76,77].
Draft guideline and formulation of the needs for further 
research
We summarized the SGR results in a draft guideline for
the following steps in development and formed a list of
specific clinical questions for further research comprising
all type-3-consistencies, type-A-inconsistencies and
incongruity from the validation process. To adjust the
research needs to the given resources these research ques-
tions were formally prioritized for the search for new evi-
dence by representatives from the targeted user groups
after conducting the SGR (outside the scope of this paper).
Resources
Our methodological concept of the systematic guideline
review had to be planned with exceedingly limited
resources for the whole project (the budget was € 75.000),
but was successfully completed after 8.5 man-months.
Starting in January 2004 with the development of the
methods concept and systematic searches for guidelines,
the first part of the SGR was finished by one researcher
(part time: 75%) by the end of June 2004, accounting for
4.5 man-months. From July 2004 to February 2005 the
validation procedure was conducted and the draft guide-
line was written by one researcher (50%), accounting for
the remaining four man-months.
Discussion
Our study addressed the need for a high-quality evidence-
based guideline to manage patients with CHF in the Ger-
man primary care context. Internationally, several high-
ranking guidelines were/are already in existence, but
adaptation methods have not been established yet
[78,79]. The guidelines included in this study were heter-
ogeneous in many respects, such as origin, coverage, and
the extent of appraised evidence. Nevertheless, the analy-
sis of these guidelines by means of the systematic guide-
line review enabled us to develop a new evidence-based
guideline on a complex condition with comparatively
limited resources. In our opinion three steps in the SGR
were responsible for resource saving in terms of net effort,
as well as for improving the validity and transparency of
the target guideline: (1) construction of a framework, (2)
consistency analysis, and (3) validation.
Framework Building
CHF is a syndrome with a number of distinct clinical pres-
entations [80]. 'Asking the right questions and asking
them right' was named as the core task of guideline devel-
opment [81], and it is essential for both appraisal of the
identified evidence [82-84] and the practical needs to be
met by a guideline. Often it is a time-consuming and un-
transparent process, and there is inevitably a trade-off
between depth and breadth of scope in accordance with
Table 3: Summarized Methodological Quality of Included Guidelines (AGREE Instrument, Standardized Domain Scores in Brackets)
Domain 1
'Scope and Purpose'
3–12 Points
Domain 2
'Stakeholder 
Involvement'
4–16 Points
Domain 3
'Rigour of 
Development'
7–28 Points
Domain 4
'Clarity and 
Presentation'
4–16 Points
Domain 5
'Application'
3–12 Points
Domain 6
'Editorial 
Independence'
2–8 Points
Median 6.5 (0.39) 8.5 (0.38) 17 (0.48) 12.5 (0.71) 4.5 (0.17) 4 (0.33)
Range 4–11 (0.11 – 0.89) 4–12 (0 – 0.67) 11–23 (0.19 – 0.76) 10–16 (0.5 – 1.0) 3–9 (0 – 0.67) 2–8 (0 – 1.0)Page 8 of 15
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Type Clinical Question Consistency Analysis† Validation Comment
Consistencies
(1) Use of ACE inhibitors in systolic 
CHF, all NYHA classes (incl. 
asymptomatic patients NYHA class 
I, with or without history of 
myocardial infarction)
16/16 'recommended' Partly justified Benefit was shown for 
symptomatic patients (all 
outcomes incl. mortality), in 
asymptomatic patients NYHA 
class I: improvement of prognosis 
and morbidity, but no evidence 
for a mortality reduction 
(see text)
Use of beta-blockers in systolic 
CHF, NYHA I post myocardial 
infarction
11/11 'recommended' Completely justified Cited sources provided the 
reported evidence in form and 
content
Use of beta-blockers in systolic 
CHF, NYHA II-III
16/16 'recommended' Completely justified Cited sources provided the 
reported evidence in form and 
content
(2) Use of aldosterone antagonists in 
systolic CHF, NYHA III/IV
16/16 'recommended' Justified Cited sources provided evidence 
on effectiveness; further research 
is needed on safety (see text)
Use of digoxin in systolic CHF with 
tachyarrhythmia
15/15 'recommended' Partly justified Evidence level were revised 
(see text)
Control of hypertension in diastolic 
CHF
2/2 'recommended' Not justified Insufficient evidence, further 
research is needed (see text)
Use of anticoagulants in patients 
with the combination of CHF and 
atrial fibrillation and/or a history of 
thromboembolism
12/12 'recommended' - No re-assessment: 
recommendations referred to 
atrial fibrillation 
(out of scope in the target 
guideline)
(4) Exercise Training 13/13 'recommended' - No re-assessment: evidence was 
to be found in a newly identified 
meta-analysis [63]
Diuretics in systolic CHF, NYHA II-
IV
14/14 'recommended' Partly justified Evidence level was revised 
(see text)
Use of hydralazine plus ISDN in 
ACE inhibitor-/ARB-intolerant 
patients
10/10 'recommended' - No re-assessment: no market 
availability for the fixed 
combination in the target 
context
Harmlessness of long-acting 
dihydropyridines
7/7 'recommended' Partly justified Evidence levels not justified; 
evidence insufficient, further 
research is needed
Inconsistencies
(B) Salt and fluid restriction 
(varying quantification)
9/10 'recommended', 1/
10 'not recommended'
- No validation: recommendations 
based on expert consensus
Beta-blockers in clinical stable 
systolic CHF, NYHA IV
13/15 'recommended', 2/
15 'not recommended'
Majority was justified, 
minority was rejected
Positive recommendations 
completely justified, negative 
recommendations based on 
insufficient evidencePage 9 of 15
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questions that were seen as relevant by other guideline
development groups, which we then prioritized and
refined to assure relevance to our setting. Thus it was a
time-saving, systematic and (by publishing it in the meth-
ods report) a transparent process.
Consistency Analysis
We carefully compared recommendations and the judg-
ments of underlying evidence reported in the guidelines.
Like Kulig et al., we found good overall (external) consist-
ency [86]. Nevertheless, many recommendations were
based only on expert consensus or weak evidence. We cat-
egorized our findings to bring to light these 'grey zones of
clinical practice' [73], but also fields of controversy in
CHF management such as BNP testing (Table 5). Our clas-
sification supported the specification of questions for fur-
ther research, and their transparent prioritization. When
supported by update-searches to ensure the timeliness of
our target guideline, the SGR prevents unnecessary repeti-
tion of extensive evidence searches and appraisals: evi-
dence-based consistencies (type-1-consistencies) allow a
focused re-appraisal of the most important evidence
sources. In type 2-consistencies further research may con-
centrate on safety aspects, as controlled studies are not
generally sufficient to identify risks or their frequency
[72].
Validation
We critically re-appraised the most important evidence
sources cited in the guidelines to assess whether design,
study-population and results were able to support the rec-
ommendations in our setting. Certainly, the vast majority
of recommendations was justified by empirical findings,
but some were not. Examples such as strong recommen-
dations for drug therapy in asymptomatic patients, which
were not sufficiently based on the highest level of evi-
dence (not being obsolete, but solely based on the con-
sensus based extrapolation of studies with patients of
higher NYHA-classes) shed a light on methodological
Beta-blockers in all systolic CHF, 
NYHA I – no matter whether post 
myocardial infarction or non-
ischemic genesis
7/8 'recommended', 1/8 
'consideration 
recommended'
Majority was not 
justified, minority was 
accepted
No evidence for strong 
recommendation (see text)
ARB in ACE intolerant patients 15/16 'recommended', 1/
16 potentially harmful 
therapy
Majority justified, 
minority rejected
Positive recommendations 
justified, negative 
recommendations based on 
insufficient evidence
†Numerical proportion of the mandating to guidelines which covered the scope and reported evidence levels and graded their recommendation. 
Type-3-consistencies – based on weak evidence – and type-A-inconsistencies are not listed in this table, as they were not included in the validation 
procedure but needed further research for evidence (a list is provided as additional web-based material, TABLE W5).
Table 4: Results of Consistency Analysis and Validation (Continued)
Table 5: Case Study about Brain Natriuretic Peptides (BNP) in the Diagnosis of Heart Failure*
Results from the SGR: The recommendations in the source guidelines on the use of BNP tests in patients suspected of heart failure showed a 
major inconsistency (type A): The test was treated in 7/16 guidelines; recommendations differed completely in content (2/7 'not recommended', 3/
7 'recommended under certain circumstances', 1/7 'recommended in every case', 1/7 'recommended ruling out CHF before an echocardiogram'), 
and in grading.
Further research: We conducted a systematic review of the diagnostic accuracy of this test in primary care. We did not find strong evidence in 
favour of its use in this setting (most studies were undertaken after referral which implies a potential spectrum bias [64,65], a clear cut-off was not 
defined, study results were inconsistent, in particular for concomitant diseases and medication) [66-69], supported by two subsequently published 
systematic reviews [70,71]. The consensus panel agreed not to recommend the test in our target guideline.
Discussion: Inconsistent recommendations in source guidelines may be due to (i) methodological shortcomings (recommendations were not setting-
specific in 6/7 guidelines that addressed both primary and secondary care; literature searches were stated to be comprehensive in only 2/7 
guidelines), or to (ii) potential conflicts of interests (4/7 guidelines did not provide any financial disclosures for the authors). Moreover, (iii) contextual 
influences may have guided the recommendations, such as availability (1/7 guidelines recommended the test, as echocardiograms are not widely 
available), access (BNP tests have market approval throughout Europe but costs are reimbursed by public funding – e.g. in the U.K. – or privately, 
e.g. in Germany), or intended resource allocation (1/7 guidelines restricted access to the more expensive echocardiogram, as CHF had to be ruled 
out by BNP and/or electrocardiogram before the referral). Last but not least the BNP test is an emerging technology where typically only limited 
information of its benefit is available, and initial studies show predominantly optimistic results [72]. Variations in the adoption of a new (healthcare) 
technology from one country to another, and also from one physician to another are shown to be large, and 'inextricably interwoven' with culture 
[72]. We know that more highly trained and committed physicians in the community tend to be 'early adopters' [72], and that specialists are less 
conservative than generalists [72,73]. It might be that the selection of guideline developing groups and their attitudes influenced the decision to 
include the BNP test.
*This test was developed to distinguish between heart failure and other conditions that show typical symptoms and signs in a patient. In this paper 
we use BNP as a synonym for itself and others such as NT-proBNP.Page 10 of 15
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quality according to the AGREE appraisal. Our reported
findings fit in well with recently published studies: McAl-
ister et al. [87] have shown that less than one-third of
treatment recommendations (and less than half of those
citing RCTs in support of the advocated treatment) were
based on high-quality evidence in national evidence-
based guidelines for common conditions, in particular
when external validity was adequately taken into account.
Also Watine et al. [42,88] demonstrated that guideline
quality was not necessarily associated with valid recom-
mendations.
Some of our judgments might seem overcritical to the
reader. But the questions on how to compare and com-
bine different sorts of evidence (e.g. benefits and risks) or
conflicting study results reflect not only the under-use of
current approaches to grade the evidence (e.g. the
GRADE- or CHEP-system) [89,90] but also epistemologi-
cal problems in evidence-based medicine [91,92]. Moreo-
ver, they point out that the concept of effectiveness is
inherently interwoven with normative values [93], which
vary depending on cultural context.
In comparison to adaptation procedures – e.g. the most
ambitious approach by Fervers et al [35] – our SGR
method differs mainly in the systematic consistency anal-
ysis and the validation procedure. Other steps are compa-
rable (the systematic search for, selection and critical
appraisal of the guideline) or necessary requirements for
the SGR (data extraction and information synthesis). Fer-
vers et al [35] emphasized the importance of proving
coherence between evidence and recommendations and
their applicability and acceptance to the target context
[79]. We have shown that consistency analyses and the
validation procedure of the SGR demonstrate coherence
and further steps in guideline development proved appli-
cability and acceptance.
Furthermore, our SGR method contributed to resource
saving: The total costs for the guideline development
(incl. the consensus process) were about € 75,000.
Though the following examples do not allow a head-to-
head comparison, they describe the context: for the 1997
Scottish guideline on 'The management of mild, non-pro-
teinuric hypertension in pregnancy' the total costs were
given as £ 66,809 (in those days about € 95,000) [94]; the
average expenditure on evidence-based guidelines of the
Agency for Health Care Policy and Research (AHCPR) in
the nineties was approximately USD1 Million per guide-
line [95], and at the beginning of 2000 the Agency for
Health Quality and Research (AHRQ) spent about USD
250,000 to conduct a systematic review [96].
Table 6: Selection of Studies for Re-assessment
Publication Type No. of Cited No. of Excluded Reason for Preclusion
Systematic Reviews/Meta-analyses (SR) 36 13 Results outdated by more recent SR
3 SR reported surrogate outcomes where clinical outcomes 
were available
2 SR did not contain target population
4 SR was out of the scope of the target guideline
Randomized Controlled Trials (RCT) 170 132 RCT included in re-evaluated SR
8 Results on surrogate outcomes where clinical outcomes were 
available
12 Set aside for further comprehensive research
12 RCT was out of the scope of the target guideline
Traditional Reviews, Editorials 33 33 Provided no systematic evidence
Miscellaneous Clinical Studies 70 69 Study design and/or sample size N<50 were not expected to 
provide strong evidence; further search for high-level 
evidence was seen to be more effective than re-appraisal
Total 309 288Page 11 of 15
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ond review in data extraction and further steps of
appraisal. Therefore, a certain observer bias cannot be
ruled out. Our budget allowed only a single AGREE
appraisal. Fortunately, we were able to compare our
results with another working group of the German Agency
for Quality in Medicine (AQuMed/ÄZQ) (two apprais-
ers), which carried out a quality appraisal of the same
guidelines subsequently and independently of us. Their
results were quite similar with a slightly better rating than
ours (see Additional file 1, Table W6). Furthermore, we
disclosed all SGR material (e.g. evidence tables) to the
participants in the consensus process and to the public
(methods report in German is available online: http://
www.allgemeinmedizin.uni-frankfurt.de/forschung2/
herzinsuffizienz_internet.html) to diminish the potential
effects of an observer bias on the target guideline.
Also, due to limited resources, we confined the publica-
tion languages to English and German, which may lead to
a system-related bias (to focus on a specific healthcare sys-
tem which may vary from the target context). However,
this bias is less probable in our study, since we included
guidelines from several countries, differing in funding and
reimbursement [97,98], availability and accessibility
[99,100] of healthcare.
Further, our findings on the resource saving effect of the
SGR have to be interpreted within the context of this
study: our paper reports on an uncontrolled N = 1 group
study and the resource data were collected retrospectively.
Nevertheless, our findings in the SGR were relevant to the
recommendations in our guideline, assured their validity,
contributed to its transparency, highlighted fields of
implicit normativity to prepare an open discourse during
the later stages of guideline development (the peer
reviews, the consensus process, and the pilot testing), and
saved resources by avoiding unnecessary redundancies in
the literature search and appraisal. Further studies should
be carried out with the involvement of a second reviewer
to avoid observer bias.
Conclusion
The systematic guideline review method is a valid means
of making use of existing guidelines, and allows a system-
atic approach to the development of a new guideline. A
systematic guideline search aims at the inclusion of guide-
lines from different healthcare systems, and a systematic
comparison of recommendations brings to light both
mainstream recommendations and controversies, but
also the grey zones of clinical practice. A careful re-evalu-
ation of the most relevant evidence sources assures valid-
ity. In the trade-off between breadth and depth, the SGR
allows reasonable and transparent prioritization in order
to concentrate the development resources on the most
important questions for further research. The SGR helps to
highlight fields of implicit normativity in guidelines and
prepares them for an open discourse within the target con-
text. It abbreviates the initial full evidence review stages,
and helps to avoid unnecessary repetition of high-quality
research by other guideline authors. In our example it
allowed the development of a guideline on the complex
clinical issue of chronic heart failure with comparatively
small resources. Further studies will have to confirm our
results to develop a valid guideline by means of the SGR.
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